Retatrutide
[CAS# 2381089-83-2]

Identification

• Classification: API >> Inhibitor drug
• Name: Retatrutide
• Synonyms: L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha -aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-Lleucyl-L-alpha -aspartyl-L-lysyl-N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-Lphenylalanyl-L-isoleucyl-L-alpha -glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-alpha -glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
• Molecular Formula: C₂₂₇H₃₅₄N₄₈O₆₉
• Molecular Weight: 4859.52
• Protein Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-a MeLeu-Leu-Asp-Lys-Lys(PEG2-?-Glu-Eicosanedioic acid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
• CAS Registry Number: 2381089-83-2
• SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC9=CC=C(C=C9)O)N

Discovery and Applications

Retatrutide, a novel medication currently under investigation, was developed by Eli Lilly and Company as a multi-receptor agonist targeting glucagon, GLP-1, and GIP receptors. The discovery of Retatrutide emerged from extensive research into metabolic hormones and their roles in regulating body weight and glucose metabolism. By simultaneously activating these three receptors, researchers aimed to create a more effective therapeutic agent for treating obesity and type 2 diabetes.

Retatrutide has several potential applications, primarily in the treatment of obesity and type 2 diabetes. Retatrutide has shown remarkable potential in promoting weight loss. By activating GLP-1, GIP, and glucagon receptors, it enhances satiety, reduces food intake, and increases energy expenditure. Clinical trials have demonstrated significant weight reduction in patients treated with Retatrutide, making it a promising option for managing obesity.

Retatrutide's ability to improve glycemic control is another key application. The drug's action on GLP-1 and GIP receptors enhances insulin secretion and inhibits glucagon release, leading to better regulation of blood glucose levels. This makes Retatrutide a valuable therapeutic option for patients with type 2 diabetes, offering the dual benefits of weight loss and improved glycemic control.

Given its effects on weight and glucose metabolism, Retatrutide may also provide cardiovascular benefits. Obesity and type 2 diabetes are major risk factors for cardiovascular disease, and weight loss combined with improved glycemic control can significantly reduce this risk.

The multi-receptor agonist approach of Retatrutide may extend its benefits to other metabolic disorders. Conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are closely linked to obesity and diabetes. By addressing the underlying metabolic dysfunctions, Retatrutide could offer therapeutic benefits for these conditions as well.

References

none